SV2A and epilepsy: It has been proposed that the molecular mechanism underlying the therapeutic effects of LEV is based on its specific binding to the synaptic vesicle protein 2 isoform A (SV2A) to inhibit the abnormal discharge of the epilepsy circuit, ultimately preventing the occurrence of seizures.14